Full text is available at the source.
Sex‐specific changes in GLP ‐ 1RA trends (2019–2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States
Sex differences in GLP-1RA use from 2019 to 2024 after FDA approval of semaglutide (Wegovy) for long-term weight management in the US
AI simplified
Abstract
In January 2024, the rate ratio (RR) for GLP-1RA utilization was 2.68 for adults and 2.74 for adolescents, indicating substantial differences between females and males.
- Prior to FDA approval of semaglutide, utilization trends were similar between males and females.
- Post-approval, the increase in GLP-1RA utilization was greater among females than males.
- This led to widened sex gaps in GLP-1RA utilization rates following the intervention.
- In nondiabetic patients, the RR was 2.86, while diabetic patients had an RR of 2.2.
- Wegovy was the leading contributor to the sex difference, with an RR of 4.03.
AI simplified